US4726952A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Slow-release sodium fluoride tablet, method of making, and method of treatment of osteoporosis
Assignee: MISSON PHARMACAL
•
Filing: 1986-03-21
•
Granted: 1988-02-23
•
Expires: 2006-03-21
Abstract
Abstract A novel use for a slow-release sodium fluoride preparation. Such slow-release sodium preparation is shown to provide a safe but effective level of fluoride in serum, optimal for the treatment of osteoporosis. It minimizes gastrointestinal side effects by limiting the amount of fluoride released in the stomach and it reduces rheumatic complications by avoiding toxic levels of fluoride in serum. The amount of fluoride absorbed is nevertheless sufficient to stimulate bone formation and prevent fractures. Thus, the maintenance of serum fluoride as encompassed in this invention, allows for a safe and effective treatment of osteoporosis.
Inventors
- 👤 Neill B. Walsdorf
- 👤 Charles Y. C. Pak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:07
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2013; A61K33/00; A61K33/16
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
84 words
In a process for the treatment of patients having osteoporosis comprising orally administering to said patients about 50 mg sodium fluoride per day the improvement consisting essentially of the step of administering 25 mg. of sodium fluoride twice a day, to maintain a serum fluoride concentration at a therapeutic level above 95 ng/ml and less than about 190 ng/ml; each 25 mg. sodium fluoride dose being in a slow-release sodium fluoride carnauba wax formulation adopted to gradually release sodium fluoride in the small intestine.
Claim 2
Dependent Claim
84 words
In a process for the treatment of patients having osteoporosis comprising orally administering to said patients about 50 mg sodium fluoride per day the improvement consisting essentially of the step of administering 25 mg. of sodium fluoride twice a day, to maintain a serum fluoride concentration at a therapeutic level above 95 ng/ml and less than about 190 ng/ml; each 25 mg. sodium fluoride dose being in a slow-release sodium fluoride carnauba wax formulation adopted to gradually release sodium fluoride in the small intestine.
Claim 3
Dependent Claim
17 words
The process of claim 1, wherein the osteoporosis is defined as being that of a post-menopausal woman.
Claim 4
Dependent Claim
17 words
The process of claim 1, wherein the osteoporosis is defined as being that of an elderly man.
Claim 5
Dependent Claim
20 words
The process of claim 1, wherein the osteoporosis may have resulted from causes, such as steroid excess or be idiopathic.
Claim 6
Dependent Claim
18 words
The process for claim 1, wherein the osteoporosis is defined as involving osteopenia (bone loss) but no facture.
References Cited (Backward Citations)
US24090A
Cited
USRE24090E
Cited
US3402240A
Cited
US3062270A
Cited
US3108046A
Cited
US3279998A
Cited
US3577514A
Cited
US4104370A
Cited
US4169885A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-02-22 | 1991-08-24 | 1992-02-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-02-22 | 1995-08-24 | 1996-02-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-02-22 | 1999-08-24 | 2000-02-23 | $7700.00 | Window Closed / Lapsed |